Partnership Potential Anagin's focus on first-in-class CNS therapies, including PTSD, TBI, Alzheimer's and Parkinson's, creates attractive licensing or co-development opportunities with large pharma and niche biotech. The company has demonstrated government funding viability through an SBIR grant, suggesting a pathway for milestone-based partnerships and asset licensing deals.

Funding Opportunities Past SBIR Phase I grant indicates capability to secure non-dilutive funding. A BD plan can identify NIH/NINDS, DoD, and other CNS-focused programs to de-risk programs, extend development runway, and align with potential partners' funding interests.

Midwest Collaboration With a lean team based in Indianapolis, Anagin could leverage the Midwest's university networks and CROs for preclinical work, trials, and patient recruitment. Target partnerships with local institutions such as Indiana universities and regional hospitals to accelerate translational programs while preserving IP control.

Data Readiness The tech stack—Google Cloud, Cloudflare, MySQL, and modern web standards—signals readiness for data-driven collaboration, secure data sharing, and regulatory-compliant partner integrations. Position Anagin as a partner for data infrastructure, translational analytics, and AI-assisted drug discovery initiatives.

Broad CNS Portfolio A broad CNS pipeline across PTSD, TBI, Depression, Neuropathic Pain, Alzheimer's, and Parkinson's offers multiple licensing angles and reduced risk through diversification. A staged BD approach focusing first on PTSD and TBI can speed partnerships, followed by broader multi-program collaborations.